Track NuCana plc — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

NuCana plc NCNA · Stock Open NuCana plc in new tab

0.9326 USD
P/E
0.02
EPS
62.04
P/B
0.15
ROE
-70.26
Beta
2.44
Loading chart...
Key Metrics
Earnings dateMarch 25, 2027
P/E0.02
EPS62.04
Book Value6.30
Price to Book0.15
Debt/Equity3.32
% Insiders0.002%
Estimates
Forward P/E-0.10
Forward EPS-9.43

DCF valuation

Model fair value for NuCana plc (NCNA)
Result
Sign in to run the valuation for NCNA.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–

NuCana plc Logo NuCana plc Analysis (NCNA)

United Kingdom Health Care Official Website Stock

Is NuCana plc a good investment? NuCana plc (NCNA) is currently trading at 0.9326 USD.

In terms of valuation, the stock trades at a P/E ratio of 0.02. This relatively low multiple may signal that NuCana plc is undervalued compared to historical market norms.

Earnings Schedule: NuCana plc is expected to release its next earnings report on March 25, 2027. The market consensus estimate for Forward EPS is -9.43.

Investor FAQ

Does NuCana plc pay a dividend?

No, it does not currently pay a dividend.

What asset class is NuCana plc?

NuCana plc is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 25, 2027. The company currently has a trailing EPS of 62.04.

Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer; Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer; and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. It has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is based in Edinburgh, the United Kingdom.

Exchange Ticker
NMS (United States) NCNA
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
April 16, 2024 1:25
Aug. 8, 2025 1:200
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion